TH-104 is under clinical development by Tharimmune and currently in Phase I for Pruritus. According to GlobalData, Phase I drugs for Pruritus have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TH-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TH-104 overview

Nalmefene (AV-104) is under development for the treatment of pruritus associated with chronic liver disease, cholestatic liver disease, atopic dermatitis (eczema) and  primary biliary cholangitis (PBC). It is administered through the buccal route in the form of film. It is being developed based on speedit transmucosal film technology. It acts by targeting kappa Type opioid receptor, Mu-type opioid receptor and interleukin 17.

Tharimmune overview

Tharimmune, formerly Hillstream BioPharma, is a biotechnology company that develops novel small molecule therapeutics for cancer treatments. Its novel therapeutic candidates target ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death (IMCD) and targeted immuno-oncology novel biologics, for the treatment of drug-resistant cancers. Tharimmune product pipeline includes HSB-1216 for novel iron-medicated cell death inducer, HSB-114 for metastatic soft tissue sarcoma (mSTS), HSB-3215 for anti-her2 antibody, HSB-1940 for anti-pd-1 (undruggable epitopes) and HSB-1216- IMCD for solid tumors. Tharimmune is headquartered in Bridgewater, New Jersey, the US.

For a complete picture of TH-104’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.